Home › Funds › Invesco › Invesco S&P SmallCap 600 (R) Pure Growth ETF
Fund family: Invesco · Filed by INVESCO EXCHANGE-TRADED FUND TRUST (CIK 1209466) · SEC series S000060799
Ticker: RZG (C000197615)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,083 with, 6 against, 0 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 2 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Invesco’s manager page (413,145 ballot items across 270 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Invesco | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 94.7% | 1,072 | 94.5% | 357,245 |
| Backed environmental and social shareholder proposals at US companies | n/a | 0 | 3.1% | 5,987 |
Each ballot item this fund voted is set against the votes of the other Invesco funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most Invesco funds on all 1,072 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 98.7% of this fund’s 1,089 such votes could be given a sector; the other 14 (1.3%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 249 | 3 | 1.2% |
| Consumer Discretionary | 245 | 2 | 0.8% |
| Industrials | 167 | 0 | 0.0% |
| Finance | 135 | 0 | 0.0% |
| Technology | 117 | 1 | 0.9% |
| Real Estate | 90 | 0 | 0.0% |
| Utilities | 25 | 0 | 0.0% |
| Consumer Staples | 17 | 0 | 0.0% |
| Telecommunications | 16 | 0 | 0.0% |
| Miscellaneous | 11 | 0 | 0.0% |
| Energy | 3 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 782 | 3 |
| Say-on-Pay | 137 | 0 |
| Audit-related | 123 | 0 |
| Compensation | 42 | 0 |
| Corporate Governance | 12 | 3 |
| Capital Structure | 5 | 0 |
| Shareholder Rights and Defenses | 2 | 0 |
| Extraordinary Transactions | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Acadian Asset Management Inc. | June 11, 2026 | $2M | 8 | 0 |
| Progyny, Inc. | May 21, 2026 | $2M | 7 | 0 |
| Protagonist Therapeutics, Inc. | June 17, 2026 | $2M | 5 | 0 |
| Clear Secure, Inc. | June 10, 2026 | $2M | 13 | 0 |
| AZZ Inc. | July 8, 2025 | $2M | 9 | 0 |
| ACM Research, Inc. | June 10, 2026 | $2M | 5 | 0 |
| DXP Enterprises, Inc. | June 12, 2026 | $2M | 8 | 0 |
| Ligand Pharmaceuticals Incorporated | June 5, 2026 | $2M | 11 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| June 9, 2026 | Etsy, Inc. | Advisory vote on a stockholder proposal to govern by majority vote. Shareholder proposal | Against | For |
| March 9, 2026 | Sanmina Corporation | To consider and vote upon the stockholder proposal entitled "Independent Board Chairman," requesting that the Board of Directors adopt a policy and amend governing documents as necessary in order that two separate people hold the office of the Chairman and the office of the CEO. Shareholder proposal | Against | For |
| May 14, 2026 | Calix, Inc. | To hold an advisory vote on a stockholder proposal relating to a simple majority vote. Shareholder proposal | For | Against |
| June 9, 2026 | Pacira Biosciences, Inc. | Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: DOMA Nominees Opposed by the Company: Oliver Benton Curtis III Shareholder proposal | Withhold | For |
| June 9, 2026 | Pacira Biosciences, Inc. | Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: DOMA Nominees Opposed by the Company: Eric de Armas Shareholder proposal | Withhold | For |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
1,104 ballot items at 128 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Invesco S&P SmallCap 600 (R) Pure Growth ETF (RZG) voted at 128 shareholder meetings of 128 companies, on 1,104 ballot items in all. Where management made a recommendation, the fund followed it on 99.4% of the items and voted against it 6 times. Its most frequent area of disagreement was director elections (3 of its votes against management). It voted on 6 shareholder proposals. It voted FOR the board's own proposals about as often as Invesco's funds as a whole (94.7% against 94.5%). It voted the same way as most Invesco funds on every item where a comparison was possible. 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Invesco’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.